{"generic":"Japanese Encephalitis Virus Vaccine, Inactivated Adsorbed","drugs":["Ixiaro","Japanese Encephalitis Virus Vaccine, Inactivated Adsorbed"],"mono":{"0":{"id":"929336-s-0","title":"Generic Names","mono":"Japanese Encephalitis Virus Vaccine, Inactivated Adsorbed"},"1":{"id":"929336-s-1","title":"Dosing and Indications","sub":{"0":{"id":"929336-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Japanese encephalitis virus disease; Prophylaxis:<\/b> primary series, 0.5 mL IM for 2 doses, 28 days apart; series should be completed at least 1 week prior to potential exposure<\/li><li><b>Japanese encephalitis virus disease; Prophylaxis:<\/b> booster dose, 0.5 mL IM may be given if ongoing exposure or reexposure is expected and the primary series of 2 doses was given more than 1 year previously<\/li><\/ul>"},"1":{"id":"929336-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and effectiveness not established in infants younger than 2 months<\/li><li>safety and effectiveness of a booster dose not established in pediatric patients younger than 17 years<\/li><li><b>Japanese encephalitis virus disease; Prophylaxis:<\/b> (aged 2 months to less than 3 years) primary series, 0.25 mL IM for 2 doses, 28 days apart; series should be completed 1 week prior to potential exposure<\/li><li><b>Japanese encephalitis virus disease; Prophylaxis:<\/b> (3 years or older) primary series, 0.5 mL IM for 2 doses, 28 days apart; series should be completed 1 week prior to potential exposure<\/li><li><b>Japanese encephalitis virus disease; Prophylaxis:<\/b> (17 years or older) booster dose, 0.5 mL IM may be given if ongoing exposure or reexposure is expected and the primary series of 2 doses was given more than 1 year previously<\/li><\/ul>"},"3":{"id":"929336-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Japanese encephalitis virus disease; Prophylaxis<br\/>"}}},"3":{"id":"929336-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929336-s-3-9","title":"Contraindications","mono":"severe allergic reaction (eg, anaphylaxis) to a previous dose of the vaccine, any other Japanese encephalitis virus vaccine, or any component of the product, including protamine sulfate <br\/>"},{"id":"929336-s-3-10","title":"Precautions","mono":"<ul><li>contains protamine sulfate; risk of hypersensitivity<\/li><li>immunocompromised patients; diminished immune response may occur<\/li><\/ul>"},{"id":"929336-s-3-11","title":"Pregnancy Category","mono":"<ul><li>B (FDA)<\/li><li>B1 (AUS)<\/li><\/ul>"},{"id":"929336-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"929336-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site (adults, 9.6%; pediatrics: 2 months to less than 1 year old, 5.3% to 17.6%; 1 to less than 3 years old, 2.5% to 6.1%; 3 to less than 18 years old, up to 5.5%), Injection site irritation, Tenderness (adults, 35.9%; pediatrics: 2 months to less than 1 year old, 0.8% to 3.1%; 1 to less than 3 years old, 1.4% to 3.1%; 3 to less than 18 years old, up to 30.9%), Injection site pain (adults, 33%; pediatrics: 1 to less than 3 years old, 3.6%; 3 to less than 18 years old, up to 18.2%), Injection site reaction (adults, 55.4%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (pediatrics: 2 months to less than 1 year old, 8.4% to 11.5%; 1 to less than 3 years old, 4.6% to 7%; 3 to less than 18 years old, up to 1.8%), Nausea (adults, 6.6%; pediatrics, up to 2.2%)<\/li><li><b>Musculoskeletal:<\/b>Myalgia (adults, 15.6%; pediatrics, 0.3% to 27.3%)<\/li><li><b>Neurologic:<\/b>Headache (adults, 27.9%; pediatrics, 1.4% to 4.6%), Irritability (pediatrics: 2 months to less than 1 year old, 8.4% to 15.3%; 1 to less than 3 years old, 2.7% to 7.7%; 3 to less than 18 years old, up to 6.1%)<\/li><li><b>Other:<\/b>Fatigue (adults, 11.3%; pediatrics, up to 12.7%), Fever (adults, 3.2%; pediatrics: 2 months to less than 1 year old, 14.5% to 23.7%; 1 to less than 3 years old, 12.7% to 20.2%; 3 to less than 18 years old, 2% to 10.7%), Influenza-like illness (adults, 12.3%; pediatrics, up to 7.7%)<\/li><\/ul><b>Serious<\/b><br\/><b>Hematologic:<\/b>Rectal hemorrhage<br\/>"},"6":{"id":"929336-s-6","title":"Drug Name Info","sub":{"0":{"id":"929336-s-6-17","title":"US Trade Names","mono":"Ixiaro<br\/>"},"2":{"id":"929336-s-6-19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"929336-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929336-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"929336-s-7","title":"Mechanism Of Action","mono":"Japanese Encephalitis Vaccine, Inactivated, Adsorbed induces antibodies that neutralize live Japanese encephalitis virus, a mosquito-borne virus, which causes Japanese encephalitis disease.<br\/>"},"9":{"id":"929336-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>(Ixiaro(R)) is for IM use only; do not administer IV, intradermally, or subQ<br\/><\/li><li><b>Intramuscular<\/b><br\/><ul><li>shake syringe well prior to administration to obtain white, opaque, homogenous suspension<\/li><li>do not mix with any other vaccine in the same syringe or vial; use separate injection sites for concomitant administration of other vaccines<\/li><li>gently twist syringe tip to remove; do not snap or pull the tip<\/li><li>(0.5 mL dose; 3 years or older) attach sterile needle for administration<\/li><li>(0.25 mL dose; 2 months to less than 3 years of age) attach sterile safety needle; with syringe in the upright position and needle uncapped, depress plunger to red line to expel extra volume into medical waste container; replace safety needle with new sterile needle for administration.<\/li><li>(aged 2 to 11 months) inject into the anterolateral aspect of the thigh<\/li><li>(1 to less than 3 years of age) inject into the anterolateral aspect of the thigh or in the deltoid if muscle mass is adequate<\/li><li>(aged 3 years or older) inject into the deltoid muscle<\/li><\/ul><\/li><\/ul>"},"10":{"id":"929336-s-10","title":"Monitoring","mono":"<ul><li>antibody titers may be indicative of efficacy<\/li><li>allergy evaluation in patients with history of severe allergic reactions to other Japanese encephalitis vaccine<\/li><li>severe hypersensitivity reactions, including signs and symptoms of anaphylaxis<\/li><\/ul>"},"11":{"id":"929336-s-11","title":"How Supplied","mono":"<b>Ixiaro<\/b><br\/>Intramuscular Suspension: 6 MCG\/0.5 ML<br\/>"},"13":{"id":"929336-s-13","title":"Clinical Teaching","mono":"<ul><li>Tell patient or caregiver to wait at least 7 days following completion of immunization schedule before traveling to foreign countries.<\/li><li>This drug may cause injection site reactions, headache, myalgia, fatigue, nausea, and fever.<\/li><li>Instruct patient or caregiver to immediately report signs of serious adverse reactions including anaphylaxis (ie, difficulty breathing, wheezing, weakness, rapid heartbeat, or hives).<\/li><li>Advise patient or caregiver of the importance of completing the immunization series.<\/li><\/ul>"}}}